Product Images Losartan Potassium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Losartan Potassium NDC 70518-1858 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Losartan Potassium 100mg 70518 1858 01
Losartan Potassium is a prescription medication available in tablet form with a strength of 100 mg. It comes in a pack of 90 tablets manufactured by Sclce in Cranbury, NJ. The medication is repackaged by RemedyRepack Inc. in Indiana, PA with an NDC # of 70518-1858-01. It is important to keep the medication out of reach of children and to see the package insert for usage instructions. It should be stored at a temperature of 20-25°C (88-77°F) with permissible excursions of 15-30°C (59-86°F) [See USP]. Lot number and expiry date are not available from the given text.*
Remedy_Label - Remedy Label
Losartan Potassium is a 100mg tablet medication, repackaged by RemedyRepack Inc from the original manufacturer Sclce, Cranbury, NJ 08512. It is in a 30 quantity pack and its usage is as directed by the package insert. The National Drug Code (NDC) is 70518-1858-00, while the source NDC is 43547-0362-11. It is advised to keep the medication out of the reach of children, and to store at a temperature range of 20-25°C (B-77°F); excursions permitted 1o 15-30°C (59-26°F) [See USP]. The Lot and Expiration numbers were not provided.*
Chemical Structure - spl image1 structure1
Figure 1 - spl image2 figure1
The text provides limited information about a study comparing the efficacy of Atenolol and Losartan Potassium in reducing the primary endpoint in patients. The study tracked patients for 66 months and reported an adjusted risk reduction of 13% for the latter drug with a p-value of 0.021.*
Figure 2 - spl image3 figure2
This is a comparison study between Atenolol and Losartan potassium in terms of their effectiveness in reducing the risk of fatal/non-fatal stroke. The adjusted risk reduction percentage for Losartan potassium is 25% with a P-value of 0.001. The table shows the percentage of patients with fatal/non-fatal strokes across different study months ranging from 6 to 66.*
Figure 3 - spl image4 figure3
This is a table showing the primary endpoint events for various demographic subgroups in a study comparing the effect of Losartan Potassium and Atenolol on stroke. The subgroups compared are based on age, gender, race, ISH, diabetes, and history of CVD. The table includes the number and rate of events, hazard ratio with a confidence interval, and symbols proportional to sample size. "Other" includes various races. Results are adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*
Figure 4 - spl image5 figure4
This is a graph that shows the percentage of patients experiencing an event over a period of 48 months while being treated with Losartan Potassium versus Placebo. The risk reduction percentage is shown as 16.1% with a p-value of 0.022.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.